+ Watch ZGNX
on My Watchlist
outperform; it has an extended release drug, approved for sale, to replace the fda discontinued meds for chronic pain. This is a 61B industry.
This drug is getting bashed and beaten down for nothing. The drug is simply vicodin without acetaminophen. Not a new scary heroin. My gosh, no drug is tamper resistant yet. Google how to shoot up oxycontin and the 3rd result tells you how to get the tamper resistance off. The FDA Mandated to the pharma industry to make pain drugs that won't hurt the liver for chronic pain sufferers. This is that drug.
Only pain management drug of its kind currently approved by the FDA. The drug doesn't damage the liver like all of its commentators. Down recently because commentator's CEO's father is a senator who introduced a bill to remove the drug over concerns for its possibly being abused. The bill has no chance of passing and the drug is going to head up sharply.
New product launches and it's an obvious buy out target
Sales of Zohydro in March 2014
drug approval chances are very high. full 2012 financial results to be announced Fri, 15th. Even if dont approved, price wont go down dramatically.
Pain killer approval
I was once a small proponent of this company, but the recent FDA decision seriously hinders Zogenix's market-beating potential, at least for the next year or so.
Great deal of insider buying. Good amount of institutional buying. Positive analyst ratings and price targets. They should be done with their public offerings, only up from here.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions